<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510311</url>
  </required_header>
  <id_info>
    <org_study_id>UMCC 2019.174</org_study_id>
    <secondary_id>HUM00167104</secondary_id>
    <secondary_id>UM-FHPG-03</secondary_id>
    <nct_id>NCT04510311</nct_id>
  </id_info>
  <brief_title>Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors</brief_title>
  <official_title>An Exploratory Study of 3-[18F]Fluoro-para-hydroxyphenethylguanidine ([18F]3F-PHPG) in Patients With Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan Rogel Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan Rogel Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this exploratory study is to test whether [18F]3F-PHPG can be used reliably to&#xD;
      map the locations of tumors in patients with neuroendocrine tumors. If so, the results of&#xD;
      this study will be used to support further development of [18F]3F-PHPG as a clinical tool for&#xD;
      neuroendocrine tumor localization and staging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in this study will be recruited from the population of adult patients with&#xD;
      neuroendocrine tumors, including pheochromocytoma and paraganglioma, being treated at the&#xD;
      University of Michigan Hospital.&#xD;
&#xD;
      The primary objective of the study is to obtain basic information on the biodistribution and&#xD;
      pharmacokinetics of [18F]3F-PHPG in cancer patients with neuroendocrine tumors.&#xD;
&#xD;
      The secondary objective of the study is to compare the diagnostic performance of [18F]3F-PHPG&#xD;
      in cancer patients with neuroendocrine tumors with the FDA approved radiopharmaceuticals&#xD;
      [123I]metaiodobenzylguanidine ([123I]MIBG) and [68Ga]DOTA-TATE in the same patients. A group&#xD;
      of approximately 12 of the subjects scanned with [18F]3F-PHPG will be recruited to undergo a&#xD;
      whole-body [123I]MIBG scan using planar scintigraphy with a gamma camera, following the&#xD;
      standard clinical protocol used at the University of Michigan. In addition, a single SPECT/CT&#xD;
      scan of the primary neuroendocrine tumor will be acquired after the whole-body scan to&#xD;
      provide a tomographic image for comparison with the positron emission tomography (PET) image&#xD;
      acquired using [18F]3F-PHPG. Several subjects enrolled on this study will undergo&#xD;
      [68Ga]DOTA-TATE scans off-study, as part of routine clinical management. Existing&#xD;
      [68Ga]DOTA-TATE scans will be obtained from consenting subjects' medical records.&#xD;
&#xD;
      This is an exploratory study and thus all statistical data analyses will be exploratory in&#xD;
      nature.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects (30 anticipated) will receive a PET/CT scan using the novel radiotracer [18F]3F-PHPG as an imaging agent. Within 60 days after the [18F]3F-PHPG PET/CT scan, approximately 12 of the subjects will also receive an FDA approved radiotracer [123I]MIBG one day prior to whole-body planar scintigraphy and SPECT/CT scans. The [123I]MIBG scans are standard clinical imaging procedures.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Image quality assessed by standardized uptake values</measure>
    <time_frame>Up to 180 minutes</time_frame>
    <description>The maximum standardized uptake value (SUVmax) of [18F]3F-PHPG in neoplastic lesions will be quantified from the PET images using region-of-interest (ROI) analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution of [18F]3F-PHPG</measure>
    <time_frame>90 minutes and 180 minutes after administration of tracer</time_frame>
    <description>Changes in the measured tissue concentrations (kBq/cc) of [18F]3F-PHPG in neoplastic lesions and abdominal organs from the two acquired PET images (acquired at 90 min and 180 min after tracer injection).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>PET/CT scan with radiotracer [18F]3F-PHPG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel radiotracer [18F]3F-PHPG prior to whole-body PET/CT scan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDA approved radiotracer [123I]MIBG prior to whole-body planar scintigraphy and SPECT/CT scan (standard clinical imaging procedures).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-[18F]Fluoro-para-hydroxyphenethylguanidine</intervention_name>
    <description>Single IV injection of 12.0 mCi (+/- 10%) [18F]3F-PHPG</description>
    <arm_group_label>PET/CT scan with radiotracer [18F]3F-PHPG</arm_group_label>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
    <other_name>[18F]3F-PHPG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[123I] metaiodobenzylguanidine</intervention_name>
    <description>Single IV injection of 10.0 mCi [123I]MIBG</description>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
    <other_name>[123I]MIBG</other_name>
    <other_name>AdreView™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Positron emission tomography/computed tomography scan</intervention_name>
    <description>Whole-body PET/CT scan performed at two time-points: 1.5 hours and 3 hours after IV injection of [18F]3F-PHPG</description>
    <arm_group_label>PET/CT scan with radiotracer [18F]3F-PHPG</arm_group_label>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
    <other_name>PET/CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Planar scintigraphy scan</intervention_name>
    <description>Whole-body scan using planar scintigraphy with a gamma camera performed the day after IV injection of [123I]MIBG</description>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Single photon emission computed tomography/computed tomography scan</intervention_name>
    <description>SPECT/CT scan of the primary neuroendocrine tumor performed the day after IV injection of [123I]MIBG</description>
    <arm_group_label>Planar scintigraphy/SPECT scans with radiotracer [123I]MIBG</arm_group_label>
    <other_name>SPECT/CT scan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current neuroendocrine tumor diagnosis&#xD;
&#xD;
          -  Able to lie flat for 60 minutes&#xD;
&#xD;
          -  Provision of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Inability to lie flat for 60 minutes&#xD;
&#xD;
          -  Currently taking medications that may alter PET scans of neuroendocrine tumors with&#xD;
             these tracers, including any of the following:&#xD;
&#xD;
               -  Tricyclic antidepressants, which inhibit the norepinephrine transporter:&#xD;
                  desipramine, amitriptyline, imipramine&#xD;
&#xD;
               -  Cold medications containing the sympathomimetic amines: phenylephrine,&#xD;
                  phenylpropanolamine, pseudoephedrine&#xD;
&#xD;
               -  Nasal decongestants (some use phenylephrine as the active agent)&#xD;
&#xD;
               -  Cocaine (which inhibits the norepinephrine transporter)&#xD;
&#xD;
               -  Tetrabenazine (Xenazine), which inhibits the VMAT2 transporter&#xD;
&#xD;
               -  Monoamine oxidase inhibitors (MAOI)&#xD;
&#xD;
               -  Some antihypertensive drugs: reserpine, labetalol, α-methyldopa, clonidine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Raffel, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Raffel, Ph.D.</last_name>
    <phone>734-936-0725</phone>
    <email>raffel@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan Rogel Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Raffel, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 10, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

